Home / Recalls / Aurolife Pharma, LLC / D-1871-2019

D-1871-2019 Class II Terminated

Recalled by Aurolife Pharma, LLC — Dayton, NJ

Recall Details

Product Type
Drugs
Report Date
September 25, 2019
Initiation Date
August 23, 2019
Termination Date
August 16, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6104 bottles

Product Description

Fexofenadine HCL Tablets USP, 180 mg, 500's BRITE STOCK; Manufactured for: Aurohealth LLC., 2572 Brunswick Pike, Lawrenceville, NJ 08648; Manufactured by: Aurolife Pharma LLC, Dayton, NJ 08810.

Reason for Recall

Failed Impurities/Degradation Specifications

Distribution Pattern

Nationwide in the USA

Code Information

Lot #s:067180011A, 067180012A, Exp 04/21, 06718027B1, Exp 09/21

Other recalls by Aurolife Pharma, LLC

  • D-0877-2023 Class III — Glycopyrrolate Tablets, USP, 1 mg, 100-count bottles, Rx Only, Distributed by: A (May 18, 2023)
  • D-0087-2023 Class II — Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only, Distributed by: Aurobin (December 16, 2022)
  • D-0736-2022 Class II — Glycopyrrolate Tablets, USP, 1 mg, 100-count bottle, Rx Only, Distributed by: Au (March 17, 2022)
  • D-1865-2019 Class II — Allergy Relief (Fexofenadine Hydrochrloride) Tablets USP, 180 mg, packaged in a) (August 23, 2019)
  • D-1874-2019 Class II — Allergy (Fexofenadine Hydrochloride) Tablets USP, 180 mg, 30-count cartons, DISC (August 23, 2019)
  • D-1867-2019 Class II — fexofenadine hydrochloride tablets USP, 180 mg, 150-count bottle, Member's Mark, (August 23, 2019)
  • D-1869-2019 Class II — Allergy Relief (Fexofenadine HCl) tablets USP, 180 mg, 15-count cartons, equate, (August 23, 2019)
  • D-1872-2019 Class II — Allergy (Fexofenadine Hydrochloride) Tablets USP, 180 mg, 30-count bottles, Dist (August 23, 2019)
  • D-1870-2019 Class II — Fexofenadine Hydrochloride Tablets USP, 180 mg, packaged in a) 15-count cartons (August 23, 2019)
  • D-1864-2019 Class II — Fexofenadine Hydrochrloride Tablets USP, 180 mg, 100-count bottle, Distributed b (August 23, 2019)